N@N

Debjit Chattopadhyay Maintained (VRTX) at Strong Buy with Increased Target to $385 on, May 2nd, 2023

^{Published on 2024-10-28 03:16:52 - WOPRAI, Debjit Chattopadhyay}
 

Debjit Chattopadhyay of Guggenheim, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $339 to $385 on, May 2nd, 2023.

Debjit has made no other calls on VRTX in the last 4 months.

There are 5 other peers that have a rating on VRTX. Out of the 5 peers that are also analyzing VRTX, 2 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Increased Target to $312 on, Wednesday, February 8th, 2023
• Do Kim of "Piper Sandler" Maintained at Hold and Held Target at $296 on, Wednesday, February 8th, 2023

These are the ratings of the 3 analyists that currently disagree with Debjit

---

• Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, March 29th, 2023
• William Pickering of "Bernstein" Initiated at Buy and Held Target at $344 on, Tuesday, March 21st, 2023
• David Risinger of "SVB Leerink" Maintained at Buy with Decreased Target to $365 on, Wednesday, February 8th, 2023

Contributing Sources

---